$VIVS

VivoSim Labs, INC. (VIVS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, VivoSim Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting

Original reporting
Published Oct 6, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$VIVS
Neutral
high confidence
Mentioned
$VIVS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VIVSNeutralLow
01

Why it matters

The disclosures introduce new share issuance capacity and a possible reverse split, which may influence liquidity and valuation.

02

Market read

First‑report corporate governance and capital‑structure changes for a micro‑cap biotech, modest trading relevance.

03

What to watch

Potential strategic shift indicated by the expanded equity incentive pool and new board members.

Relevance 6/10Novelty 7/10Timing: today

Background

VivoSim Labs filed a Form 8‑K detailing shareholder approvals for governance changes and capital structure adjustments.

Company-level read

Ticker impact

$VIVSNeutralHigh confidence
Context

SEC 8‑K reports approval of a reverse stock split, equity incentive plan amendment and director elections for VivoSim Labs.

Expected impact

potential short‑term pressure as investors price dilution from the equity plan and anticipate the reverse split.

Evidence & confidence

The filing is the first public disclosure of these actions; market participants will adjust valuations accordingly.

Market effects

Limited; primarily impacts the biotech/clinical‑trial sector where VivoSim operates.

Minor effect on US micro‑cap market.

Low; no broader macro implications.

Counterpoint

If the reverse split tightens float, the stock could rally on reduced supply despite dilution concerns.

Key entities

  • VivoSim Labs, Inc.

    US‑listed biotech firm filing the 8‑K.

  • Keith Murphy

    Elected Class III director and executive chairman.

  • Adam Stern

    Elected Class III director.

Related articles

$VIVSMed

FDA updates regulations to allow non-animal drug safety testing

The FDA updated regulations to allow non-animal methods for drug safety testing, replacing 'animal tests' with 'nonclinical tests'. VivoSim Labs (VIVS) offers 3D human cellular models for preclinical testing, aiming to reduce drug development costs by identifying toxic molecules early. The company's models use primary human cells and could help avoid costly failures in clinical trials.

$VIVSMed

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

$VIVSMed

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.